Print pageHome » Genzyme Gains Approval for Framingham Site, a Boost to Fabrazyme Production
Genzyme Gains Approval for Framingham Site, a Boost to Fabrazyme Production
Reuters
01/24/2012
January 24, 2012 -- Sanofi's unit Genzyme said on Tuesday it had won U.S. regulatory approval for its Framingham, U.S.-based plant that will produce Fabrazyme, aiming to get patients back on their required dosages of the rare disease drug worldwide this year.
The opening of the plant, which won clearance from the European regulator last week, is a critical step in resolving manufacturing woes that have bedeviled Genzyme since before Sanofi acquired the U.S. rare disease specialist last year. "With this approval, we continue upon our 2012 plan to restore unconstrained supply for all patients globally throughout the course of the year," Genzyme Chief Executive David Meeker said in a statement.
A viral contamination at one of Genzyme's plants in 2009 has resulted in shortages of both Fabrazyme, its drug for Fabry disease, and Cerezyme for Gaucher's disease.
The new biologics production plant, based in the state of Massachusetts, should help remove capacity constraints and enable Genzyme to win back market share it lost to Shire's Replagal.
Genzyme said it would begin to move the most severely affected patients in Europe to full dose of Fabrazyme in the first quarter of this year. Patients in the U.S. who are already using the drug, will be returned to full dosing in March.
Worldwide, the complete return to normal supply levels of Fabrazyme will begin in the second quarter and continue throughout the year, it said. (Reporting by Caroline Jacobs)
More News:
-
05/17/2012
Study: US Clears Drugs Faster Than Europe, CanadaFrom WSJ.com
Researchers say the U.S. approved more new medicines in less time than Europe and Canada in the last decade, challenging long-standing criticisms that the Food and Drug Administration lags behind its peers in clearing important new drugs.
-
05/10/2012
Ex-Sanofi Chemist Sentenced To 18 Months For Trade Secrets TheftFrom WSJ.com
A 30-year-old former research chemist for pharmaceutical firm Sanofi was sentenced to 18 months in prison for stealing Sanofi trade secrets and making them available through another company, the U.S. Department of Justice said.
-
04/27/2012
Novo Nordisk Expanding U.S. Workforce 15 Percent
Most new positions are in sales and management, but manufacturing jobs will be added in Clayton, N.C.
-
04/26/2012
AstraZeneca’s Brennan to Retire; Lowth Named Interim CEOFrom Bloomberg.com
AstraZeneca Chief Executive Officer David Brennan will retire from his post, ending a six- year tenure after repeated failures in drug development left investors skeptical of the company’s earnings prospects.
-
04/19/2012
Congress Pushing to Allow Generic Drug Manufacturers to Make Label ChangesFrom Pharmalot
The U.S. Congress has introduced bills that would allow generic makers to make updates to labels as new safety and efficacy information becomes available.
- 04/18/2012 GSK Shifts to Unassigned Seating in RTP Offices
- 04/17/2012 Amgen CEO Comes Clean: I Was Arrogant and an Awful Listener
- 04/16/2012 Product News: Growth Direct Systems for Environmental Monitoring and Sterility
-
04/12/2012
J&J Fined $1.2 Billion in Drug CaseFrom NYTimes.com
A judge in Arkansas ordered Johnson & Johnson and a subsidiary to pay more than $1.2 billion in fines on Wednesday, a day after a jury found that the companies had minimized or concealed the dangers associated with an antipsychotic drug.
- 04/11/2012 Humira Set to Become World's Top-Selling Drug
- All news »
Get Connected Now!
- Featured White Papers
Sponsored Links
